Navigation Links
Indevus Pharmaceuticals Announces Retirement of David B. Sharrock From Its Board of Directors
Date:10/22/2007

nancial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA(R), SANCTURA(R) XR, NEBIDO(R) , VANTAS(R) and SUPPRELIN(R) LA; the early state of products under development; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR(R); risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; competition; need for additional funds and corporate partners, including for the development of our products; failure to acquire and develop additional product candidates; changes in reimbursement policies and/or rates for SANCTURA, VANTAS, SUPPRELIN LA, DELATESTRYL(R) and any future products; history of operating losses and expectation of future losses; product liability and insurance uncertainties; risks relating to the Redux- related litigation; the risk that the businesses of Indevus and Valera Pharmaceuticals, Inc. will not be integrated successfully during the period following the related merger; the risk that the cost savings and any other synergies from the merger may not be fully realized or may take longer to realize than expected; market acceptance for the merger and approved products; risks of regulatory review and clinical trials; disruption from the transaction making it more difficult to maintain relationships with customers, employees or suppliers; competition and its effect on pricing, spending, third-party relationships and revenues; reliance on in
'/>"/>
SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Speaker announces business members of IT Task Force
4. Doyle announces technology tax credits for Berbee
5. Doyle announces new energy, global warming policies
6. Doyle announces $80M renewable energy strategy
7. GE announces first installation of Discovery VCT
8. UWM announces winners of RGI awards
9. Third Wave announces two senior management appointments
10. Mirus announces new method for making antibodies
11. Merge announces sofware updates, upcoming acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... 22, 2014 Invisible Sentinel Inc., ... the food and beverage industries, announced today that ... under a non-exclusive agreement by Enartis, a global ... Enartis, an Esseco Group company headquartered in Trecate, ... California and other global markets for their own ...
(Date:9/22/2014)...  Neogen Corporation (Nasdaq: NEOG ) announced ... its 2015 fiscal year, which ended Aug. 31, was ... of $7,839,000 in the first quarter of last year. ... 2013, earnings per share in the current quarter were ... First quarter revenues increased 15% to $67,599,000, from the ...
(Date:9/22/2014)... 22, 2014  WIRB-Copernicus Group (WCG), the world,s ... for clinical research, announced today that its Western ... reaccredited by the Association for the Accreditation of ... improve safeguards for clinical research participants. ... , Ph.D., commented, "It is of utmost importance ...
(Date:9/22/2014)... 2014 METTLER TOLEDO is pleased ... measuring device CNS110 ScanTape™ . Replacing a ... offering greater ease and accuracy for transport and ... significantly enhance productivity—an important benefit for load planning ... equals profits. , Usable at any point ...
Breaking Biology Technology:Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 2Invisible Sentinel's Test for Wine-Spoilage Microbe to be Distributed by Enartis in Multiple Markets Globally 3Neogen reports 13% net income increase 2Neogen reports 13% net income increase 3Neogen reports 13% net income increase 4Neogen reports 13% net income increase 5Neogen reports 13% net income increase 6Neogen reports 13% net income increase 7Western IRB (WIRB) Awarded AAHRPP Reaccreditation 2ScanTape™ Handheld Dimensioner Increases Processing Volume 2
... EXTON, Pa., July 15 Morphotek((R)), Inc., a subsidiary of ... a privately held biotechnology company specializing in the development of ... evaluation and option agreement in which Morphotek will evaluate monoclonal ... , The agreement with CII provides Morphotek ...
... , SHANGHAI, July 15 /PRNewswire-Asia-FirstCall/ ... Company"), a leading Chinese firm,specializing in the manufacture, research, ... financial results for,the fourth quarter and fiscal year ended ... Quarter 2009 Highlights, -- Net sales ...
... First Half of 2009 (Excluding Technical, Plastics) ... Business, - Sales Decline in the Cyclical Segments of ... In the first half of 2009, Gerresheimer AG achieved sales ... was,mainly attributable to sales growth for pharmaceutical packaging and systems,with which Gerresheimer ...
Cached Biology Technology:Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies 2Morphotek(R), Inc. and Cancer Innovations, Inc. Announce Evaluation and Option Agreement for Therapeutic Monoclonal Antibodies 3China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 2China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 3China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 4China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 5China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 6China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 7China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 8China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 9China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 10China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 11China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 12China-Biotics, Inc. Reports Fourth Quarter and Full Year Fiscal 2009 Financial Results 13Gerresheimer Holds its own in Difficult Environment 2Gerresheimer Holds its own in Difficult Environment 3Gerresheimer Holds its own in Difficult Environment 4
(Date:9/22/2014)... CHAMPAIGN, Ill. Antarctic fishes that manufacture their ... Southern Ocean also suffer an unfortunate side effect, ... inside their bodies resist melting even when temperatures ... the Proceedings of the National Academy of ... be an undesirable consequence of the evolution of ...
(Date:9/22/2014)... seven institutions in the country selected by the ... year,s BEST Award a $2 million grant ... promising biomedical sciences graduate trainees to career opportunities ... have traditionally taken. , The award funds development ... Scientists (iJOBs) program. It includes courses, seminars, shadowing, ...
(Date:9/22/2014)... Most of the fires captured in this image burn in ... of Okhotsk. Dozens of red hotspots, accompanied by plumes of ... or grey, blows to the east towards the Sea of ... north of this area, swampy forest inhabit the central depression, ... , While large wildfires are common in Russia in the ...
Breaking Biology News(10 mins):Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 2Study: Antifreeze proteins in Antarctic fishes prevent freezingand melting 3Rutgers receives $2 million grant to prepare biomedical students for roles in industry 2Rutgers receives $2 million grant to prepare biomedical students for roles in industry 3
... York, NY (April 18, 2013) An excess of ... psychosis in people who are at risk for schizophrenia, ... Center (CUMC) published in the current issue of ... diagnostic tool for identifying those at risk for schizophrenia ...
... has been presented today to Professor Adolfo Diez-Perez, MD, ... Hospital del Mar, Director of the Bone and Joint ... and Professor of Medicine at the Autonomous University of ... IOF Medal of Achievement every two years to honour ...
... fatty and sugary foods. Or do they? New research contradicts ... have the same taste in food and highlights the importance ... preferences. SINC Until now the scientific ... sugary drinks, the very foods that are the most damaging ...
Cached Biology News:High levels of glutamate in brain may kick-start schizophrenia 2IOF Medal of Achievement awarded to Professor Adolfo Diez-Perez 2Tell me where you're from and I'll tell you what tastes you prefer 2
...
...
... >95%NEN Radiolabeled Ligands\n\nReceptor-related research has long been ... radiolabeled ligands selected to keep pace with ... of products and services for receptor research ... radioligands. If you do not find exactly ...
... TURBO DNase (patent pending) was developed using a ... into the DNA binding pocket of wild-type DNase ... the protein for DNA. The result is a ... for DNA, and an ability to maintain at ...
Biology Products: